Supriya Lifescience Peer Comparison
NSE: SUPRIYA | BSE: 543434
₹852.45
₹-36.80
(-4.14%)
As on 08-Oct-2026 13:19IST
Market cap
₹6,908 Cr
Revenue (TTM)
₹873 Cr
P/E Ratio
34.8
P/B Ratio
5.7
Div. Yield
0.1 %
Edit
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
6,908 | 19,960 | 19,617 | 17,270 | 16,203 |
Revenue (₹ Cr) |
873 | 1,682 | 2,287 | 2,570 | 3,230 |
Net Profit (₹ Cr) |
198.37 | 273.51 | 678.07 | 735.15 | 666.92 |
Net Margin (%) |
22.44 | 16.19 | 28.10 | 26.88 | 20.60 |
RoE (%) |
17.43 | 11.15 | 19.73 | 19.16 | 18.75 |
Price to Earnings |
34.82 | 67.13 | 29.48 | 23.49 | 25.16 |
Price-To-Book |
5.65 | 7.43 | 5.34 | 3.92 | 4.02 |
Income Statement (₹ Cr)
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
872.55 | 1,682.47 | 2,287.33 | 2,569.77 | 3,229.67 |
|
Total Income
|
884.01 | 1,689.83 | 2,413.29 | 2,735.39 | 3,237.12 |
|
Total Expenditure
|
582.74 | 1,203.91 | 1,490.75 | 1,628.14 | 2,090.06 |
|
EBITDA
|
289.80 | 478.55 | 796.58 | 941.63 | 1,139.61 |
|
Depreciation
|
30.90 | 126.01 | 78.10 | 57.58 | 281.06 |
|
EBIT
|
258.91 | 352.55 | 718.48 | 884.05 | 858.55 |
|
Interest
|
1.75 | 52.11 | 0.88 | 7.69 | 190.64 |
|
Other Income
|
11.46 | 7.37 | 125.96 | 165.62 | 7.45 |
|
Exceptional Items
|
-0.46 | 12.16 | 0.00 | -49.16 | -17.24 |
|
Profit before Tax
|
268.16 | 319.96 | 843.56 | 992.82 | 658.12 |
|
Provision for Tax
|
69.79 | 46.45 | 165.49 | 257.67 | -8.80 |
|
Profit after Tax
|
198.37 | 273.51 | 678.07 | 735.15 | 666.92 |
Liabilities (₹ Cr)
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,197.73 | 2,591.20 | 3,586.42 | 4,202.90 | 3,902.67 |
|
Minority Interest
|
0.00 | 0.00 | -12.71 | 0.00 | -21.81 |
|
Non-Current Liabilities
|
38.33 | 266.35 | 28.74 | 91.50 | 1,392.75 |
|
Current Liabilities
|
121.04 | 848.06 | 385.94 | 627.48 | 2,077.10 |
|
Total Liabilities
|
1,357.11 | 3,705.61 | 4,037.51 | 4,921.88 | 7,246.72 |
Assets (₹ Cr)
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
818.70 | 2,525.44 | 1,291.22 | 770.28 | 5,617.77 |
|
Current Assets
|
532.30 | 1,109.77 | 2,585.66 | 3,803.22 | 1,539.85 |
|
Total Assets
|
1,357.11 | 3,705.61 | 4,037.51 | 4,921.88 | 7,246.72 |
|
Total Debt*
|
0.00 | 657.97 | 0.57 | 2.50 | 2,309.68 |
|
Net Current Assets
|
411.26 | 261.71 | 2,199.72 | 3,175.74 | -537.25 |
|
Contingent Liabilities
|
8.81 | 160.01 | 17.53 | 370.49 | 51.57 |
Cashflow (₹ Cr)
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
185.77 | 342.18 | 523.24 | 967.57 | 537.99 |
|
Cash Flow from Investing Activities
|
-176.17 | -325.92 | -582.30 | -561.67 | -369.46 |
|
Cash from Financing Activities
|
-9.88 | 13.62 | -46.46 | -798.31 | -313.53 |
|
Net Cash Inflow / Outflow
|
-0.29 | 29.88 | -105.52 | -392.41 | -145.00 |
Ratios
Profitability Ratios
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
25.30 | 11.43 | 24.97 | 23.39 | 14.47 |
|
ROE (%)
|
17.43 | 11.15 | 19.73 | 19.16 | 18.75 |
|
ROA (%)
|
16.07 | 7.80 | 18.69 | 14.95 | 9.26 |
|
EBIT Margin (%)
|
29.67 | 20.95 | 31.41 | 34.40 | 26.58 |
|
Net Margin (%)
|
22.44 | 16.19 | 28.10 | 26.88 | 20.60 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
28.14 | 27.91 | 15.01 | 10.69 | 9.59 |
|
EBIT Growth (%)
|
13.70 | 58.32 | 18.45 | 24.14 | 16.84 |
|
Net Profit Growth (%)
|
11.38 | 149.56 | 19.61 | -9.09 | 62.68 |
|
EPS Growth (%)
|
11.57 | -3.57 | 17.73 | 14.40 | 67.41 |
|
Book Value Growth (%)
|
20.16 | 9.67 | 26.75 | -0.34 | 36.71 |
Valuation Ratios
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
36.05 | 74.81 | 30.29 | 22.63 | 24.09 |
|
Price / Book Value
|
5.86 | 7.81 | 5.49 | 3.96 | 3.95 |
|
Dividend Yield (%)
|
0.11 | 0.06 | 0.30 | 1.97 | 0.00 |
|
EV/EBITDA
|
24.45 | 45.10 | 24.03 | 15.24 | 15.93 |
|
Market Cap (₹ Cr)
|
4,548.18 | 6,819.66 | 11,439.22 | 21,592.90 | 17,980.08 |
Solvency Ratios
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.07 | 0.00 | 0.00 | 0.24 |
|
Short term debt to equity ratio
|
-- | 0.16 | 0.00 | 0.00 | 0.12 |
|
Current Ratio
|
4.40 | 1.31 | 6.70 | 6.06 | 0.74 |
|
Quick Ratio
|
3.08 | 0.88 | 5.59 | 5.31 | 0.53 |
|
Interest Coverage
|
154.15 | 7.14 | 959.59 | 130.11 | 4.45 |
Operating Efficiency Ratios
| Supriya Lifescience | Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.15 | 30.84 | 36.10 | 7.07 | 21.07 |
|
Asset Turnover
|
0.71 | 0.48 | 0.63 | 0.52 | 0.45 |
|
Receivable days
|
70.59 | 113.81 | 121.68 | 26.06 | 63.88 |
|
Inventory Days
|
55.45 | 84.76 | 63.83 | 65.95 | 43.27 |
|
Payable days
|
133.19 | 101.94 | 108.28 | 81.01 | 151.85 |
|
Cash Conversion Cycle
|
-7.15 | 96.62 | 77.23 | 11.00 | -44.70 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
